| Half-life | 2.6 hours |
| Tmax | 1 h |
| Bioavailability | 100 % (approx) |
| Protein Binding | 20 % |
| Volume of Distribution | 0.3 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Typical dose 600 mg IV q12h (adjust for renal impairment). |
Severity: Moderate
Adverse Effects:
GI upset, neutropenia, rash
Contraindications:
Immediate beta-lactam anaphylaxis
Precautions:
CBC monitoring recommended if prolonged therapy